Zoetis Inc (ZTS)
158.43
+5.07
(+3.31%)
USD |
NYSE |
Apr 26, 16:00
158.43
0.00 (0.00%)
After-Hours: 20:00
Zoetis Enterprise Value: 74.74B for April 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
April 25, 2024 | 74.74B |
April 24, 2024 | 73.60B |
April 23, 2024 | 73.00B |
April 22, 2024 | 71.16B |
April 19, 2024 | 71.60B |
April 18, 2024 | 74.63B |
April 17, 2024 | 74.09B |
April 16, 2024 | 74.58B |
April 15, 2024 | 73.10B |
April 12, 2024 | 73.19B |
April 11, 2024 | 79.03B |
April 10, 2024 | 79.25B |
April 09, 2024 | 81.05B |
April 08, 2024 | 80.39B |
April 05, 2024 | 80.46B |
April 04, 2024 | 80.31B |
April 03, 2024 | 79.14B |
April 02, 2024 | 80.07B |
April 01, 2024 | 80.99B |
March 28, 2024 | 82.00B |
March 27, 2024 | 81.68B |
March 26, 2024 | 80.38B |
March 25, 2024 | 81.36B |
March 22, 2024 | 81.86B |
March 21, 2024 | 81.59B |
Date | Value |
---|---|
March 20, 2024 | 82.81B |
March 19, 2024 | 83.71B |
March 18, 2024 | 82.68B |
March 15, 2024 | 83.54B |
March 14, 2024 | 84.14B |
March 13, 2024 | 85.21B |
March 12, 2024 | 87.56B |
March 11, 2024 | 88.54B |
March 08, 2024 | 87.93B |
March 07, 2024 | 87.63B |
March 06, 2024 | 88.55B |
March 05, 2024 | 89.33B |
March 04, 2024 | 90.54B |
March 01, 2024 | 91.89B |
February 29, 2024 | 95.33B |
February 28, 2024 | 96.07B |
February 27, 2024 | 95.64B |
February 26, 2024 | 94.74B |
February 23, 2024 | 94.82B |
February 22, 2024 | 94.57B |
February 21, 2024 | 90.78B |
February 20, 2024 | 89.94B |
February 16, 2024 | 90.78B |
February 15, 2024 | 91.36B |
February 14, 2024 | 88.81B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
48.55B
Minimum
Mar 23 2020
120.20B
Maximum
Dec 29 2021
80.85B
Average
81.25B
Median
Enterprise Value Benchmarks
Biogen Inc | 34.94B |
Eli Lilly and Co | 711.57B |
Pfizer Inc | 201.07B |
Abbott Laboratories | 193.05B |
Bristol-Myers Squibb Co | 117.94B |
Enterprise Value Related Metrics
Net Income (Quarterly) | 525.00M |
Revenue (Quarterly) | 2.213B |
Total Expenses (Quarterly) | 1.504B |
EPS Diluted (Quarterly) | 1.14 |
Gross Profit Margin (Quarterly) | 67.10% |
Profit Margin (Quarterly) | 23.72% |
Earnings Yield | 3.20% |
Operating Earnings Yield | 4.19% |
Normalized Earnings Yield | 3.242 |